Latest News - Kala Pharmaceuticals

Monday, January 08, 2018 | Clinical Trials, Kala Pharmaceuticals

Kala Pharmaceuticals Announces NDA for Inveltys Has Been Accepted for Review by FDA

Kala Pharmaceuticals announced that the new drug application (NDA) for Inveltys (KPI-121 1%), a topical twice-a-day product candidate for the treatment of inflammation and pain in patients who have un…

Read the full story

Friday, January 05, 2018 | Clinical Trials, Dry Eye, Kala Pharmaceuticals

Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials of KPI-121 0.25% in Dry Eye Disease

Kala Pharmaceuticals announced topline results from its two phase 3 clinical trials, STRIDE 1 and STRIDE 2 (STRIDE - Short Term Relief In Dry Eye), evaluating the safety and efficacy of KPI-121 0.25% …

Read the full story

Monday, November 13, 2017 | Management/Leadership, Kala Pharmaceuticals

Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer

Kala Pharmaceuticals announced the appointment of Todd Bazemore as Chief Operating Officer of the company. He will report directly to Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmace…

Read the full story

Wednesday, October 25, 2017 | Cataract Surgery, Clinical Trials, Kala Pharmaceuticals

Kala Pharmaceuticals Submits New Drug Application to FDA for Inveltys

Kala Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for Inveltys (KPI-121 1%), a topical twice-a-day product candidate for the treatment of inflammation and pa…

Read the full story

Wednesday, July 26, 2017 | Earnings & Financials, Kala Pharmaceuticals

Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters’ Option

Kala Pharmaceuticals announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters’ exercise in full of their option to purchase an additio…

Read the full story

Thursday, July 20, 2017 | Earnings & Financials, Kala Pharmaceuticals

Kala Pharmaceuticals Announces Pricing of Initial Public Offering

Kala Pharmaceuticals announced that is has priced its initial public offering of 6,000,000 shares of its common stock at a public offering price of $15 per share, for aggregate gross proceeds of appro…

Read the full story

Monday, May 01, 2017 | Clinical Trials, Kala Pharmaceuticals

Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery

Kala Pharmaceuticals announced positive topline results from its confirmatory phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery. KP…

Read the full story